Imagine facing a rare genetic disorder that affects your body's ability to process nitrogen—this is the reality for those with ornithine transcarbamylase deficiency (OTC).
OTC is a rare inherited disorder affecting the urea cycle, which is crucial for preventing ammonia buildup within the bloodstream. About 1 in 14,000 to 1 in 80,000 individuals have OTC, and some develop permanent damage.
This article provides a comprehensive overview of ornithine transcarbamylase deficiency, exploring its causes, symptoms, diagnosis, treatment options, and living with the condition.
[signup]
What is Ornithine Transcarbamylase Deficiency?
Ornithine transcarbamylase deficiency (OTC) is the most prevalent genetic disorder of the urea cycle. It's caused by a missing or damaged OTC gene and characterized by ammonia building up in the bloodstream.
OTC is more common among boys than girls. Its symptoms tend to be more severe when they appear shortly after birth (early onset OTC).
Ammonia is a waste product the body produces after breaking down proteins. When not addressed, it can build up in the brain and cause permanent, severe brain damage.
The ornithine transcarbamylase enzyme plays a vital role in the urea cycle, converting ammonia to urea in the liver before it travels to the kidneys to be safely excreted via urine.
Ornithine transcarbamylase deficiency is an X-linked disorder because the affected gene is on the X chromosome. That's why boys most often develop it.
OTC's severity ranges from mild neurocognitive deficits to being potentially lethal if left untreated. Early identification and treatment are crucial to preventing severe neurological damage and life-threatening complications.
Symptoms and Diagnosis
Recognizing early symptoms and promptly treating ornithine transcarbamylase deficiency is vital to avoid permanent impairment.
Recognizing Symptoms
The signs and symptoms of OTC include:
Infants
- Increased sleep
- Lethargy
- Vomiting
- Breathing rate irregularities (rapid breathing)
- Changes in body temperature/hypothermia
- Respiratory alkalosis (alkaline blood)
- Poor sucking
- Inability to feed
- Hyperventilation
- Developmental delays
- Failure to thrive
- Irritability
- Seizures
- Coma
- Brain damage (intellectual disability, cerebral palsy, etc.)
- Death
Ornithine transcarbamylase deficiency is most common among newborn boys; symptoms often appear within 24 hours to several days after birth (early-onset form of the disorder). When detected early, many more severe or permanent symptoms can be avoided.
Adolescents and Adults
OTC deficiency is more often observed in babies and early childhood than later in life.
However, a less severe form of ornithine transcarbamylase deficiency, called partial OTC deficiency or late-onset OTC deficiency, may develop in older children, adolescents, and young adults (particularly among females).
Examples of late-onset symptoms include:
- Nausea
- Vomiting
- Migraines or early morning headaches
- Intermittent confusion
- Developmental delays
- Cognitive deficits
- Erratic or aggressive behavior
- Delirium
- Learning or intellectual disabilities
- Attention-deficit/hyperactivity disorder (ADHD)
- Executive function deficits
- Fatigue
- Loss of appetite
- Behavioral challenges
- Seizures and other neurological symptoms
- Brain dysfunction
- Liver problems
- Coma
- Death
Sometimes, these symptoms are mild and go unnoticed. Other individuals experience more severe symptoms after eating meat due to its high protein load. Symptoms may also worsen due to stressors.
Diagnostic Methods
Diagnosing ornithine transcarbamylase deficiency involves genetic testing and screening blood ammonia levels.
Infants with OTC deficiency may be identified via newborn screening programs. However, these screenings are not mandatory in all U.S. states.
When OTC deficiency newborn screenings aren't required, the condition can be diagnosed after evaluating for symptoms of the disorder, reviewing medical history, blood testing, and completing a physical exam.
Based on the Longitudinal Study of Urea Cycle Disorders criteria, OTC diagnoses require specific clinical and biochemical findings, including elevated glutamine, elevated ammonia, low-to-normal citrulline levels, and one or more of the following:
- Variant in OTC gene via molecular genetic testing
- Increased orotic acid excretion
- Decreased OTC enzyme activity in the liver (liver biopsy in males)
Differential diagnosis requires distinguishing OTC deficiency from similar conditions causing ammonia buildup, such as other urea cycle disorders, fatty acid oxidation defects, organic acidemias, and pyruvate metabolism disorders.
Examples of a differential diagnosis for hyperammonemia in a newborn male include:
- Argininosuccinate synthetase (ASS) deficiency
- Argininosuccinate lyase (ASL) deficiency
- Carbamoyl phosphate synthetase I (CPSI) deficiency
- Fulminant hepatitis with fulminant liver failure
- N-acetyl glutamate synthase (NAGS) deficiency
The differential diagnosis for late-onset OTC disease includes the following in addition to those listed above:
- Multiorgan failure
- Portal vein thrombosis
- Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome
- Acetaminophen toxicity and other acute liver failure
- Citrin deficiency
Effective diagnosis is critical to establish the most effective treatment.
Treatment and Management
Ornithine transcarbamylase deficiency management and treatment consists of medical solutions, dietary changes, and long-term management strategies.
Medical Treatments
Medical treatments often include medications that reduce ammonia levels and hemodialysis in severe cases. Rapid correction of high ammonia levels to 200 µmol/L or less is encouraged.
Hemodialysis is the most effective method of rapidly eliminating excess ammonia and is often needed if blood ammonia levels are above 500 µmol/L.
Intravenous arginine hydrochloride can help manage metabolic decompensation and hyperammonemia, while supplementing arginine to reduce catabolic protein breakdown.
Sodium phenylacetate, sodium benzoate, sodium phenylbutyrate, and glycerol phenylbutyrate help "scavenge" excess ammonia, offering an alternate pathway for nitrogen excretion.
While intravenous (IV) sodium phenylacetate and sodium benzoate are used in acute settings, oral sodium benzoate or sodium phenylbutyrate are effective for long-term maintenance.
Dietary Management
Dietary management in individuals with ornithine transcarbamylase deficiency includes following a lower-protein meal plan, using dietary supplements, and seeking nutritional support as needed.
Consuming enough calories is vital to reverse and prevent protein breakdown (catabolism). Initially, the calories should be protein-free.
After normalizing ammonia levels, protein can be slowly reintroduced within 24-48 hours at a maximum intake of 2 grams per kilogram of body weight daily. Individuals with OTC deficiency should continue to follow a lower-protein meal plan.
Amino acids (citrulline and arginine), vitamins, trace minerals, and essential fatty acids are often useful dietary supplements for people with ornithine transcarbamylase deficiency. Infants must use special infant formulas or foods.
A doctor or dietitian can help these individuals control their protein intake, consume adequate calories, and take the most appropriate dietary supplements.
Long-Term Management Strategies
Long-term management strategies for individuals with OTC deficiency include routine medical monitoring and check-ups, as well as having emergency protocols in place in the case of hyperammonemia.
Long-term management aims to avoid recurrent hyperammonemia and optimize development using a low-protein diet, sufficient calories to prevent catabolism, nitrogen scavenger therapies, and nutritional supplementation.
Liver transplantation is also effective for correcting OTC, as repeated ammonia level spikes can lead to permanent brain damage.
Living with Ornithine Transcarbamylase Deficiency
To avoid complications, living with ornithine transcarbamylase deficiency involves routine medical monitoring and corrective care.
It's vital to seek treatment at the first sign of symptoms, follow treatment guidelines precisely as directed, and learn coping strategies for dietary restrictions and other lifestyle changes.
Undergo periodic blood testing to assess ammonia and amino acid levels. Genetic testing is encouraged for individuals with a family history of OTC.
Counseling and support groups help enhance social and emotional well-being in individuals with OTC and their family members. Examples of helpful resources include:
- Genetic Testing Registry
- Clinicaltrials.gov
- National Library of Medicine
- National Organization for Rare Disorders
- Genetic and Rare Diseases Information Center
- UCT in Common
- OTC Hope
- National Urea Cycle Disorders Foundation
Educational and workplace accommodations for people with ornithine transcarbamylase deficiency are highly beneficial.
Advances in Research and Future Directions
Advances in research and technology can help guide future ornithine transcarbamylase deficiency treatment decisions.
Numerous clinical trials are being conducted nationwide to better understand OTC deficiency and potential new advances in medical treatments and long-term management.
Current research trends include gene therapy prospects and novel medications. Future treatments could include personalized medicine approaches, stem cell technology, and more.
Participating in research trials offers the ability to try new, innovative OTC deficiency treatments and receive medical monitoring at no cost.
[signup]
Key Takeaways
- Ornithine transcarbamylase (OTC) deficiency is a rare genetic disorder, though the most common of the urea cycle disorders.
- It involves a damaged or missing ornithine transcarbamylase enzyme, the enzyme required to convert ammonia to urea in the liver for safe excretion. Ammonia buildup can cause brain damage and other severe symptoms when not addressed.
- Managing ornithine transcarbamylase deficiency consists of nitrogen-scavenging medicines, hemodialysis as needed, nutritional adjustments (lower protein diet), dietary supplements, long-term management, and ongoing medical care.
- Awareness and continued research are vital to improve the lives of individuals affected by OTC deficiency.
- Explore our related articles, subscribe to our newsletter for updates on urea cycle disorders, and share your experiences in the comments section below!
%201.svg){kind=logo}
